^
    1m
    Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer. (PubMed, Adv Sci (Weinh))
    Mechanistic investigations reveal that this combination therapy increases the abundances of tumor-infiltrating lymphocytes and elicits potent systemic antitumor immunity that inhibits local tumors and regresses abscopal metastases. The observed synergistic effect of VG161 and RT encourages further clinical translation.
    Journal
    |
    PPP1R15A (Protein Phosphatase 1 Regulatory Subunit 15A)
    |
    VG161
    4ms
    A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Virogin Biotech Ltd.
    New P2 trial
    |
    VG201
    5ms
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=27 --> 12
    Enrollment closed • Enrollment change
    |
    GPC3 (Glypican 3)
    |
    AGAR T cells
    6ms
    An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=195, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2026 --> Jun 2026 | Trial primary completion date: Dec 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    8ms
    TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8+ T-cell subsets in lymph nodes and tumors. (PubMed, J Immunother Cancer)
    Our findings demonstrate that combination therapy targeting immune cells critical for antitumor responses and blocking immune-suppressive environment significantly improves antitumor therapeutic efficacy. These findings provide a strong basis for using HCW9218 to enhance the efficacy of ICIs against solid tumors in the clinical setting.
    Journal
    |
    CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1) • IL15 (Interleukin 15)
    |
    HCW9218
    8ms
    An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=195, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    9ms
    HCW9218 for Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=21, Completed, ImmunityBio, Inc. | Active, not recruiting --> Completed | N=60 --> 21
    Trial completion • Enrollment change
    |
    HCW9218
    9ms
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Baylor College of Medicine | N=24 --> 14
    Enrollment change
    |
    GPC3 (Glypican 3) • IL15 (Interleukin 15)
    |
    AGAR T cells
    9ms
    A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SAR445877
    9ms
    HCW9218 in Select Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Completed, Masonic Cancer Center, University of Minnesota | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Feb 2025
    Trial completion • Trial completion date
    |
    HCW9218
    9ms
    A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=542, Recruiting, Sanofi | N=291 --> 542 | Trial completion date: Nov 2028 --> Jun 2028
    Enrollment change • Trial completion date • First-in-human
    |
    MSI (Microsatellite instability)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Yervoy (ipilimumab) • muzastotug (ADG126) • SAR445877
    10ms
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Feb 2040 --> Aug 2040
    Enrollment closed • Trial completion date
    |
    GPC3 (Glypican 3)
    |
    AGAR T cells